Accéder au contenu
Merck
Toutes les photos(1)

Documents

C-093

Supelco

Cyclosporin A solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C62H111N11O12
Numéro CAS:
Poids moléculaire :
1202.61
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in acetonitrile

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−70°C

Chaîne SMILES 

O=C(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@H](C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N([C@H](C(C)C)C(N(C)[C@@H]([C@@H]([C@H](C)C/C=C/C)O)C1=O)=O)C)=O)=O)=O)=O)=O)CC(C)C)=O)=O)CN(C)C([C@@H](N1)CC)=O

InChI

1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50?,51+,52-/m1/s1

Clé InChI

PMATZTZNYRCHOR-VPYFBNRVSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

A Certified Spiking Solution® of an immunosuppressant and narrow therapeutic index drug used to prevent rejection in organ transplantation. This certified calibration material is suitable for critical quantitative applications in clinical and diagnostic testing such as therapeutic drug monitoring assays to ensure patients remain within the drug′s narrow therapeutic range.  The Snap-N-Spike® format allows laboratories to eliminate weighing operations of hazardous substances such as cyclosporin A, significantly reducing occupational exposure hazards related to handling of acutely toxic powders, and provides the ability to spike into their matrix of choice just before use.

Application


  • Novel IgE crosslinking-induced luciferase expression method using human-rat chimeric IgE receptor-carrying mast cells: This study leverages Cyclosporin A′s immunosuppressive properties to explore new methodologies for investigating allergic responses. By utilizing Cyclosporin A to modulate immune cell activity, researchers have developed an innovative in vitro assay that significantly enhances our understanding of immune mechanisms, demonstrating Cyclosporin A′s pivotal role in immunological research and its application in developing more effective allergy treatments (Akiyama H et al., 2024).

  • Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics: This review discusses the critical role of Cyclosporin A in the development of nanocarrier systems for targeted drug delivery, particularly for ocular applications. Cyclosporin A′s effectiveness in preventing transplant rejection and its properties as a calcineurin inhibitor make it an excellent candidate for incorporation into advanced drug delivery systems, enhancing therapeutic efficacy and reducing systemic side effects (Datta D et al., 2024).

  • A sterilizable platform based on crosslinked xanthan gum for controlled-release of polymeric micelles: Demonstrating Cyclosporin A′s utility in enhancing the efficacy of controlled-release drug systems, this study details the use of Cyclosporin A with a novel xanthan gum-based platform. This research emphasizes Cyclosporin A′s role in the pharmaceutical industry, particularly in improving drug delivery mechanisms that can be crucial for treating chronic conditions (Signorini S et al., 2024).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Produit(s) apparenté(s)

Pictogrammes

FlameHealth hazardExclamation mark

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Flam. Liq. 2

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

35.6 °F - closed cup

Point d'éclair (°C)

2 °C - closed cup


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Tip W Loo et al.
Biochemistry, 52(41), 7167-7169 (2013-10-03)
There is no high-resolution crystal structure of the human P-glycoprotein (P-gp) drug pump. Homology models of human P-gp based on the crystal structures of mouse or Caenorhabditis elegans P-gps show large differences in the orientation of transmembrane segment 5 (TM5).
Jane Rasaiyaah et al.
Nature, 503(7476), 402-405 (2013-11-08)
Human immunodeficiency virus (HIV)-1 is able to replicate in primary human macrophages without stimulating innate immunity despite reverse transcription of genomic RNA into double-stranded DNA, an activity that might be expected to trigger innate pattern recognition receptors. We reasoned that
Koichi Watashi et al.
Hepatology (Baltimore, Md.), 59(5), 1726-1737 (2014-01-01)
Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide. Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clinically available as anti-HBV agents, emergence of drug-resistant viruses highlights the need for new anti-HBV agents interfering with other
David A Williams et al.
Pediatric blood & cancer, 61(5), 869-874 (2013-11-29)
Randomized clinical trials in pediatric aplastic anemia (AA) are rare and data to guide standards of care are scarce. Eighteen pediatric institutions formed the North American Pediatric Aplastic Anemia Consortium to foster collaborative studies in AA. The initial goal of
Derek J Hausenloy et al.
British journal of pharmacology, 165(5), 1235-1245 (2011-10-01)
Ischaemic heart disease (IHD) is the leading cause of death and disability worldwide. The pathophysiological effects of IHD on the heart most often result from the detrimental effects of acute ischaemia-reperfusion injury (IRI) on the myocardium. Therefore, novel therapeutic targets

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique